


## Nexopamil racemate

## Chemical Properties

CAS No.:	116759-35-4
Formula:	C <sub>24</sub> H <sub>40</sub> N <sub>2</sub> O <sub>3</sub>
Molecular Weight:	404.59
Appearance:	N/A
Storage:	0-4°C for short term (days to weeks), or -20°C for long term (months).



## Biological Description

Description	Nexopamil racemate is the racemate of Nexopamil. Nexopamil is a combined Ca <sup>2+</sup> /5-HT <sub>2</sub> antagonist on platelet aggregation in vitro and on thrombus formation in vivo.
Targets(IC <sub>50</sub> )	5-HT <sub>2</sub> Receptor: None
In vitro	Serotonin-induced platelet aggregation in dog platelet-rich plasma (PRP) in vitro was most potently inhibited by ketanserin (IC <sub>50</sub> 0.55 x 10 <sup>-8</sup> M), followed by nexopamil (IC <sub>50</sub> 0.81 x 10 <sup>-7</sup> M) and gallopamil (IC <sub>50</sub> 1.76 x 10 <sup>-6</sup> M). Because serotonin is an important pathophysiologic mediator in unstable angina, 5-HT <sub>2</sub> receptor antagonism should be of considerable benefit by preventing platelet activation and aggregation. The combination with calcium-antagonistic activity leads to an increase in coronary blood flow (CBF) and a decrease in cardiac oxygen demand.
In vivo	Nexopamil (0.05 mg/kg) completely abolished CFRs during the first 30 min after application without significantly altering hemodynamics. The same effect was noted with 0.02 mg/kg ketanserin (5-HT <sub>2</sub> /alpha 1 antagonist). The Ca <sup>2+</sup> antagonist gallopamil reduced CFRs only in the highest hemodynamically tolerable dose by 40%.

## Solubility Information

Solubility	< 1 mg/ml refers to the product slightly soluble or insoluble
------------	---

## Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.472 mL	12.358 mL	24.716 mL
5 mM	0.494 mL	2.472 mL	4.943 mL
10 mM	0.247 mL	1.236 mL	2.472 mL
50 mM	0.049 mL	0.247 mL	0.494 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. The storage conditions and period of the stock solution: - 80 °C for 6 months; - 20 °C for 1 month. Please use it as soon as possible.

## Reference

1. Kirchengast M, et al. Inhibition by the combined Ca<sup>2+</sup> and 5-HT<sub>2</sub> receptor antagonist nexopamil (LU 49938) of intracoronary thrombus formation in a canine model of arterial stenosis and intimal damage. J Cardiovasc Pharmacol. 1993 Nov;22(5):687-94.

Inhibitors · Natural Compounds · Compound Libraries

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use.

Tel:781-999-4286

E-mail:[info@targetmol.com](mailto:info@targetmol.com)

Address:36 Washington Street,Wellesley Hills,MA 02481